Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

CeNeRx, PharmaNess to develop novel cannabinoid compounds
June 2007
SHARING OPTIONS:

RESEARCH TRIANGLE PARK, N.C.CeNeRx BioPharma Inc., a biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system, announced it signed an agreement with PharmaNess Neuroscience giving CeNeRx the rights to a series of novel cannabinoid compounds that selectively target the CB1 and CB2 cannabinoid receptors. Under the terms of the agreement, CeNeRx has been granted an exclusive worldwide license to develop, manufacture and commercialize the PharmaNess cannabinoid portfolio, currently including over a dozen preclinical compounds. These compounds may have broad utility, including cannabinoid agonists for pain, glaucoma and other CNS-related disorders, and cannabinoid antagonists for obesity. The collaboration between CeNeRx and PharmaNess also includes drug discovery efforts aimed at further expanding their joint cannabinoid portfolio.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.